Chase Pharma raises $12M for Alzheimer's R&D

Chase Pharmaceuticals, which is helmed by ex-Allergan ($AGN) president Doug Ingram, has raised $12 million, according to a filing with the SEC. The startup is working on a therapy that can be used to allow for higher doses of donepezil in treating Alzheimer's patients. The company has been keeping a low profile so far, and its website is largely a placeholder for what's being planned. Ingram was named CEO back in late 2015. Filing

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.